[
    [
        {
            "time": "2021-10-19",
            "original_text": "恒瑞医药三季报净利润同比下降1.21%，研发费用创历史新高 盈利能力下降",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "三季报",
                    "净利润",
                    "同比下降",
                    "研发费用",
                    "历史新高"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药三季报净利润同比下降1.21%，研发费用创历史新高 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-19",
            "original_text": "恒瑞医药第三季度营收跌逾14%，净利连续两季度同比下降 盈利能力下降",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "第三季度",
                    "营收",
                    "下跌",
                    "净利",
                    "同比下降"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药第三季度营收跌逾14%，净利连续两季度同比下降 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-19",
            "original_text": "恒瑞医药Q3营收69亿元，全球布局临床研究加快创新",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "Q3",
                    "营收",
                    "临床研究",
                    "创新"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药Q3营收69亿元，全球布局临床研究加快创新",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-19",
            "original_text": "再创历史新高！恒瑞医药前三季研发投入41.42亿元占营收20.5%",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "研发投入",
                    "历史新高",
                    "营收占比"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "再创历史新高！恒瑞医药前三季研发投入41.42亿元占营收20.5%",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-18",
            "original_text": "A股融资融券日报：两融余额增加74.53亿元",
            "features": {
                "keywords": [
                    "A股",
                    "融资融券",
                    "两融余额",
                    "增加"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额增加74.53亿元",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        }
    ]
]